The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models
Neuro-Oncology · 2024
DOI: 10.1093/neuonc/noae066 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, 2024. Verfasst von Daniel de la Nava und 31 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Clínica Universidad de Navarra, Pamplona, Spain. Hauptthemen laut MEDLINE: Oncolytic Virotherapy, Glioma, Brain Neoplasms, Xenograft Model Antitumor Assays. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: European Research Council, Gobierno de Navarra, NCI NIH HHS.
Abstract (Originalsprache)
Background
Pediatric high-grade gliomas (pHGGs), including diffuse midline gliomas (DMGs), are aggressive pediatric tumors with one of the poorest prognoses. Delta-24-RGD and ONC201 have shown promising efficacy as single agents for these tumors. However, the combination of both agents has not been evaluated.
Methods
The production of functional viruses was assessed by immunoblotting and replication assays. The antitumor effect was evaluated in a panel of human and murine pHGG and DMG cell lines. RNAseq, the seahorse stress test, mitochondrial DNA content, and γH2A.X immunofluorescence were used to perform mechanistic studies. Mouse models of both diseases were used to assess the efficacy of the combination in vivo. The tumor immune microenvironment was evaluated using flow cytometry, RNAseq, and multiplexed immunofluorescence staining.
Results
The Delta-24-RGD/ONC201 combination did not affect the virus replication capability in human pHGG and DMG models in vitro. Cytotoxicity analysis showed that the combination treatment was either synergistic or additive. Mechanistically, the combination treatment increased nuclear DNA damage and maintained the metabolic perturbation and mitochondrial damage caused by each agent alone. Delta-24-RGD/ONC201 cotreatment extended the overall survival of mice implanted with human and murine pHGG and DMG cells, independent of H3 mutation status and location. Finally, combination treatment in murine DMG models revealed a reshaping of the tumor microenvironment to a proinflammatory phenotype.
Conclusions
The Delta-24-RGD/ONC201 combination improved the efficacy compared to each agent alone in in vitro and in vivo models by potentiating nuclear DNA damage and in turn improving the antitumor (immune) response to each agent alone.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, Clínica Universidad de Navarra, Pamplona, Spain.
- Solid Tumor Program, Center for the Applied Medical Research, Pamplona, Spain.
- Health Research Institute of Navarra (IdiSNA), Pamplona, Spain.
- Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Jack Martin Fund Division of Pediatric Hematology-oncology, Mount Sinai, New York, USA.
- Division of Oncology and Children's Research Center, DIPG/DMG Research Center Zurich, University Children's Hospital Zurich, Zurich, Switzerland.
ORCID-Profile: Daniel de la Nava, Iker Ausejo-Mauleon, Virginia Laspidea, Javad Nazarian, Carl Koschmann, Matthew D Dun, Marta M Alonso
Förderung
- European Research Council
- Gobierno de Navarra
- NCI NIH HHS
- NINDS NIH HHS
- Instituto de Salud Carlos III
Zitieren
APA
de la Nava, D., Ausejo-Mauleon, I., Laspidea, V., Gonzalez-Huarriz, M., Lacalle, A., Casares, N., Zalacain, M., Marrodan, L., García-Moure, M., Ochoa, M. C., Tallon-Cobos, A. C., Hernandez-Osuna, R., Marco-Sanz, J., Dhandapani, L., Hervás-Corpión, I., Becher, O. J., Nazarian, J., Mueller, S., Phoenix, T. N., …, & Alonso, M. M. (2024). The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models. Neuro-Oncology. https://doi.org/10.1093/neuonc/noae066
Vancouver
de la Nava D, Ausejo-Mauleon I, Laspidea V, Gonzalez-Huarriz M, Lacalle A, Casares N, et al. The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models. Neuro-Oncology. 2024. doi:10.1093/neuonc/noae066
BibTeX
@article{delaNava2024,
author = {de la Nava, Daniel and Ausejo-Mauleon, Iker and Laspidea, Virginia and Gonzalez-Huarriz, Marisol and Lacalle, Andrea and Casares, Noelia and Zalacain, Marta and Marrodan, Lucía and García-Moure, Marc and Ochoa, Maria C and Tallon-Cobos, Antonio Carlos and Hernandez-Osuna, Reyes and Marco-Sanz, Javier and Dhandapani, Laasya and Hervás-Corpión, Irati and Becher, Oren J and Nazarian, Javad and Mueller, Sabine and Phoenix, Timothy N and van der Lugt, Jasper and Hernaez, Mikel and Guruceaga, Elizabeth and Koschmann, Carl and Venneti, Sriram and Allen, Joshua E and Dun, Matthew D and Fueyo, Juan and Gomez-Manzano, Candelaria and Gallego Perez-Larraya, Jaime and Patiño-García, Ana and Labiano, Sara and Alonso, Marta M},
title = {The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models},
journal = {Neuro-Oncology},
year = {2024},
doi = {10.1093/neuonc/noae066}
}
EUVIMED